Prevalence percentages and odds ratios for primary outcome (death or loss-to-follow-up) from the logistic regression analysis.

<p>OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; SD: Standard deviation; PI: Protease inhibitor; Anaemia: Haemoglobin concentration <12 g/dL in women and <13 g/dL in men.</p><p>Prevalence percentages and odds ratios for primary outcome (death or loss-to-follow-up) from the logistic regression analysis.</p

Attrition Rate at 36-month follow up of the cohort in the public sector comparing with MSF (H) cohort.

<p>N: Number; LTF: Loss to follow up; MSF (H): Médecins Sans Frontières (Holland); DOH: Department of Health.</p><p>Attrition Rate at 36-month follow up of the cohort in the public sector comparing with MSF (H) cohort.</p

Clinical baseline characteristics of study population.

<p>IQR: Interquartile range.</p><p>WHO definition of Anaemia: Haemoglobin concentration <12 g/dL in women and <13 g/dL in men.</p><p>Clinical baseline characteristics of study population.</p

CONSORT diagram for analysis, with a total number of enrolled patients, number of patients for survival analysis and number of patients to estimate risk factors for attrition.

<p>CONSORT diagram for analysis, with a total number of enrolled patients, number of patients for survival analysis and number of patients to estimate risk factors for attrition.</p

Clinical baseline characteristics of study population, continued.

<p>BMI: Body mass index; SD: Standard deviation; NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor.</p><p>Clinical baseline characteristics of study population, continued.</p

Unadjusted Kaplan-Meier survival curves of non-prior ART group and prior ART group, full cohort (N = 10,223).

<p>Log-rank test for equality of survival χ2 (1 df) = 122.10; p<0.001.</p

Unadjusted Kaplan-Meier curves, by first-line ART regimen.

<p>Unadjusted Kaplan-Meier curves, by first-line ART regimen.</p

Flexible parametric survival model of potential determinants for attrition among study population (N = 5,718).

<p>CI: Confidence interval; BMI: Body mass index; PI: Protease inhibitor; WHO definition of Anaemia: Haemoglobin concentration <12 g/dL in women and <13 g/dL in men.</p><p>#- not significant in univariate models.</p><p>Note: Early enrolment (1 Sep 2005 to 31 Dec 2009), and Late enrolment (1 Jan 2010 to 20 Oct 2011).</p><p>Flexible parametric survival model of potential determinants for attrition among study population (N = 5,718).</p

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

Introduction: Linezolid is a last-resort antibiotic for infections caused by multidrug-resistant microorganisms. It is widely used for off-label indications and for longer than recommended treatment durations, exposing patients at higher risk of adverse drug reactions (ADRs), notably thrombocytopenia. This study aimed to investigate ADR incidence and risk factors, identify thrombocytopenia-related trough levels based on treatment duration, and evaluate the performance of predictive scores for ADR development.Methods: Adult in- and outpatients undergoing linezolid therapy were enrolled in three hospitals and ADRs and linezolid trough levels prospectively monitored over time. A population pharmacokinetic (pop-PK model) was used to estimate trough levels for blood samples collected at varying times.Results: A multivariate analysis based on 63 treatments identified treatment duration ≥10 days and trough levels >8 mg/L as independent risk factors of developing thrombocytopenia, with high trough values correlated with impaired renal function. Five patients treated for >28 days did not develop thrombocytopenia but maintained trough values in the target range (Conclusion: Our work supports the necessity of establishing guidelines for dose adjustment in patients with renal insufficiency and the systematic use of TDM in patients at-risk in order to keep trough values ≤8 mg/L. The Buzelé predictive score (if ≥7) may help to detect these at-risk patients, and pop-PK models can estimate trough levels based on plasma samples collected at varying times, reducing the logistical burden of TDM in clinical practice.</p